GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (FRA:IMR) » Definitions » Shiller PE Ratio

AC Immune (FRA:IMR) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 2016. Start your Free Trial

What is AC Immune Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AC Immune Shiller PE Ratio Historical Data

The historical data trend for AC Immune's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Shiller PE Ratio Chart

AC Immune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AC Immune Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AC Immune's Shiller PE Ratio

For the Biotechnology subindustry, AC Immune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AC Immune's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AC Immune's Shiller PE Ratio falls into.


;
;

AC Immune Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AC Immune's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, AC Immune's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.199/107.7224*107.7224
=-0.199

Current CPI (Mar. 2025) = 107.7224.

AC Immune Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 0.148 100.464 0.159
201509 0.332 99.785 0.358
201512 -0.093 99.386 -0.101
201603 -0.102 99.475 -0.110
201606 0.215 100.088 0.231
201609 -0.165 99.604 -0.178
201612 -0.084 99.380 -0.091
201703 -0.159 100.040 -0.171
201706 -0.202 100.285 -0.217
201709 -0.131 100.254 -0.141
201712 0.068 100.213 0.073
201803 -0.171 100.836 -0.183
201806 -0.164 101.435 -0.174
201809 -0.186 101.246 -0.198
201812 -0.186 100.906 -0.199
201903 0.805 101.571 0.854
201906 -0.215 102.044 -0.227
201909 0.229 101.396 0.243
201912 -0.256 101.063 -0.273
202003 -0.104 101.048 -0.111
202006 -0.205 100.743 -0.219
202009 -0.241 100.585 -0.258
202012 -0.250 100.241 -0.269
202103 -0.208 100.800 -0.222
202106 -0.238 101.352 -0.253
202109 -0.203 101.533 -0.215
202112 -0.250 101.776 -0.265
202203 -0.225 103.205 -0.235
202206 -0.224 104.783 -0.230
202209 -0.166 104.835 -0.171
202212 -0.233 104.666 -0.240
202303 -0.212 106.245 -0.215
202306 -0.205 106.576 -0.207
202309 -0.187 106.570 -0.189
202312 -0.053 106.461 -0.054
202403 -0.186 107.355 -0.187
202406 -0.239 107.991 -0.238
202409 0.053 107.468 0.053
202412 -0.171 107.128 -0.172
202503 -0.199 107.722 -0.199

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AC Immune  (FRA:IMR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AC Immune Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AC Immune's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AC Immune Business Description

Traded in Other Exchanges
Address
EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

AC Immune Headlines

No Headlines